ACAsbjørg S. Christophersen

Asbjørg S. Christophersen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Asbjørg S. Christophersen has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Use of alcohol and drugs by employees in selected business areas in Norway: a study using oral fluid testing and questionnaires

    by Hilde Marie Erøy Edvardsen, Inger Synnøve Moan, Asbjørg S. Christophersen, Hallvard Gjerde

    Alcohol or drug use and associated hangover may reduce workplace safety and productivity and also cause sickness absence. The aims of this study were to examine (i) the use of alcohol and drugs, and (ii) reduced efficiency at work and absence due to such use among employees. Forty-four companies were invited; half of them agreed to participate. Employees filled in a questionnaire and provided a sample of oral fluid, which was analysed for alcohol, 12 psychoactive medicinal drugs and 6 illicit drugs. Participation was voluntary and anonymous. Two thousand four hundred thirty-seven employees in eight business areas agreed to participate (92 % of those invited). By combining questionnaires and oral fluid testing, we found that 5.2 % had used psychoactive medication during the last couple of days, 1.4 % had used illicit drugs, 17.0 % had used alcohol during the last 24 h but only one person (0.04 %) was positive for alcohol in oral fluid. About 25 % reported reduced efficiency at work, and 5 % reported absence from work due to alcohol use during the past 12 months. The use of illicit drugs and binge drinking resulting in reduced efficiency and absence was most common among restaurant and bar workers and more common among men than women, whereas use of psychoactive medication was most common among healthcare, transportation and storage workers. Impairment at work due to alcohol or drugs was rare, whereas reduced efficiency due to drinking was reported by a fairly large proportion. There were marked differences between some business areas, and across gender.


  • Open Access

    Use of alcohol and drugs by Norwegian employees: a pilot study using questionnaires and analysis of oral fluid

    by Hallvard Gjerde, Asbjørg S Christophersen, Inger S Moan, Borghild Yttredal, J Michael Walsh, Per T Normann, Jørg Mørland

    The use of alcohol and drugs may affect workplace safety and productivity. Little is known about the magnitude of this problem in Norway.


  • Frequent Detection of Benzodiazepines in Drugged Drivers in Norway

    by Asbj⊘Rg S. Christophersen, J⊘Rg M⊘Rland

    Objective. To describe the Norwegian system for handling suspected drugged driving cases according to an impairment-based law, with primary focus on benzodiazepines (BZDs), blood concentrations and combination with other psychoactive compounds. Methods. Routines for handling suspected driving under the influence of drugs other than alcohol are described. These include primary police investigation, blood sampling, and clinical tests of impairment performed by a police physician, a standard analytical program covering the most relevant illegal drugs and medicines relevant to traffic safety (approximately 25 compounds), and expert witness statements prepared for the court. The drug use patterns, blood drug concentrations, and frequency of multi-drug use have been recorded, with primary focus on benzodiazepines (BZDs). Use of BZDs among apprehended drivers has been compared with patient prescriptions recorded for the same BZDs. Results. One or more drugs have been detected in approximately 80% of the cases received for analysis every year. BZDs have been the most prevalent drugs and have been detected in 38–57% of the cases, which is more frequent than other common illegal drugs; e.g., tetrahydrocannabinol (THC; 30–43%) and amphetamine (33–39%). The majority of the BZDs have been detected at supratherapeutic blood concentrations and frequently in combination with illegal drugs, other psychoactive medicines, or alcohol. Less than 5% of the BZDs (except for nitrazepam – 7.6%) have been found to be the only drug present at therapeutic blood levels. The majority of the drivers were 20–39 years old (median age 29–33), while the majority of BZDs prescribed were to users over 50 years of age. Conclusions. Drivers with BZD detected are probably not representative of ordinary patients with BZD prescriptions, as shown by the age disparity of drivers and patients. The frequent detection of BZDs suggests that these compounds should be included in the analytical program used for blood samples from apprehended drivers and for studies on drug involvement in road traffic accidents and risk calculations.


    • 1 March 2007
      • Vol. 127  (5) , 583-4

    [Cannabis affects driving skills].

    by Hassan Z Khiabani, Asbjørg S Christophersen, Jørg Mørland

    Delta (9)-tetrahydrocannabinol (THC), the most important psychoactive substance in cannabis, is frequently detected in blood from apprehended drivers suspected for drugged driving. Both experimental and epidemiological studies have demonstrated the negative effects of THC upon cognitive functions and psychomotor skills. These effects could last longer than a measurable concentration of THC in blood. Culpability studies have recently demonstrated an increased risk of becoming responsible in fatal or injurious traffic accidents, even with low blood concentrations of THC. It has also been demonstrated that there is a correlation between the degree of impairment, the drug dose and the THC blood concentration. It is very important to focus on the negative effect of cannabis on fitness to drive in order to prevent injuries and loss of human life and to avoid large economic consequences to the society.

    • 1 March 2007
      • Vol. 127  (5) , 618-9

    [Routines upon suspicion of driving under influence].

    by Hassan Z Khiabani, Asbjørg S Christophersen, Jørg Mørland

    Norway was the first country in the world to introduce an act, in 1936, that prohibits driving with a blood alcohol concentration (BAC) above 0.5 g/kg. This Norwegian Road Traffic Act was expanded in 1959 to include illegal drugs and other medicinal psychoactive drugs. Upon suspicion of drugged driving, a clinical test for impairment (CTI) is performed and blood samples are taken. The Norwegian police have been allowed to request blood analysis for illegal and prescribed drugs affecting driving performance, even by force if drug influence is suspected. There is currently no legal limit for drugs other than alcohol. The Division of Forensic Toxicology and Drug Abuse (DFTDA) at the Norwegian Institute of Public Health analyse blood samples from all drivers suspected of drugged driving in Norway. Based on results of the blood sample analysis and the CTI, the DFTDA makes a preliminary conclusion of the probability of impairment comparable to BAC above 0.5 g/kg. Then the prosecuting authority decides whether to charge the suspected driver. The impairment has to be proven to the court in each individual case. The court decision is based on the outcome of the CTI, the blood sample analyses, other information that may be given and in most cases an expert witness statement. The sentences can be conditional or unconditional imprisonment, depending on the BAC or the degree of drug impairment and withdrawal of the driving licence for a period of at least 2 years..

  • Open Access

    Plasma concentrations during naltrexone implant treatment of opiate‐dependent patients

    by Linda Olsen, Asbjørg S. Christophersen, Grete Frogopsahl, Helge Waal, Jørg Mørland

    Aims: To evaluate individual variations in plasma concentrations over time in patients with naltrexone implants.Methods: Ten opioid‐dependent patients received up to four implants. Plasma samples were collected regularly for the analyses of naltrexone and the metabolite β‐naltrexol.Results: The median naltrexone Cmax was 12.3 (range 5.8–22.1) ng ml−1, the median Tmax was 1 day (range 3 h to 35 days), and the median length of time that plasma concentrations were above 1 ng ml−1 was 55 (range 30–80) days. Two patients reported heroin use without experiencing any effect. Tissue reactions were recorded in two patients after repeated implantation.Conclusion: Marked individual and intraindividual variations in naltrexone concentrations were observed. Further studies should be performed to evaluate the need for therapeutic drug monitoring during naltrexone implant treatment.


    • 26 June 2003
      • Vol. 123, 1841-3

    [Impaired driving as an indicator of drug abuse: what consequences for treatment?].

    by Asbjørg S Christophersen, Svetlana Skurtveit, Jørg Mørland

    Driving under the influence of drugs is a growing problem as the number of apprehended drivers in Norway has increased 2.5 times since 1990. At least two drugs are usually detected. The majority of offenders have been arrested earlier. This paper gives an overview of studies of impaired drivers. The re-arrest rate among 1102 drivers under the influence of drugs was followed for 7.5 years and compared with a group of 850 drivers under the influence of alcohol. Another study included 874 drivers with benzodiazepine detections followed retrospectively for 11 years. Earlier arrests and drugs detected first time were recorded. The third study recorded deaths among drugged (n = 918) and drunken (n = 2531) drivers for 7.5 years, compared with same age group in the general population. 57% of drugged and 28% of drunken drivers were re-arrested. More the 60% of drivers with benzodiazepine detections had been arrested earlier. Alcohol was most the commonly detected substance at first arrest. The standardised mortality ratio for male drugged drivers was 18.1 (14.9-21.8), for drunken drivers 3.7 (2.9-4.7). Our results show that drugged drivers represent risk groups with multi-drug use, frequent re-arrests and early death. Other efforts combined with fines, prison and withdrawal of driving licence should be considered. Some countries have follow-up programmes that include control of drug use by urine testing before a re-issue of the driving licence is considered.

    • 12 June 2003
      • Vol. 123  (12) , 1660-1

    [Naltrexone implants--a pilot project].

    by Helge Waal, Asbjørg S Christophersen, Grethe Frogopsahl, Linda Helen Olsen, Jørg Mørland

    An increasing number of Norwegian heroin addicts have had naltrexone implants abroad without proper documentation. The authors established a joint project to study duration and safety. Methodology to measure naltrexone in plasma was developed. 10 patients had 21 implants. Plasma samples were collected before, one and three hours after implantation, daily for one week, then weekly. Patient satisfaction, side effects and unwanted medical events were recorded. Patients had a protective level of naltrexone for 35-80 days. Side effects were few. Two patients had abstinence reactions caused by insufficient detoxification. Two patients had their repeat implants removed because of tissue reactions. One patient developed hepatitis C infection in the second week after implantation. One had transient increase in transaminases after heavy multi-drug use. The others were without signs of hepatic toxicity. Use of implants secures a prolonged period of naltrexone protection. Implants are mostly well tolerated, but tissue reactions to repeat implants could be a problem. Evaluation of the patients should be thorough and the treatment integrated in a competent follow up.